Bronchial hyper-responsiveness (BHR) is defined as an abnormal responsiveness of the airways which determines an increased air flow obstruction on exposure to different stimuli. Classically, these stimuli have been divided into specific stimuli such as allergens and chemicals, and non-specific stimuli such as histamine, methacholine, cold air and exercise. Nevertheless, this classification does not seem completely adequate since the so-called non-specific stimuli also act through different and specific mechanisms. Although some authors feel that BHR is acquired during life, there is evidence that constitutional and familial or genetic factors play a major role in predisposing to BHR. The risk of BHR is related to the degree and the severity of atopy. In allergic asthmatics, BHR increases during prolonged exposition to inhaled allergens (e.g. during the pollen season) and significantly decreases after adequate environmental control. 6, 7 There is also a strong association between the degree of BHR and asthma severity and medication requirement, and BHR is considered to be a risk factor for the outcome of childhood asthma.
Although the factors that may contribute to BHR are still incompletely known, there is today strong evidence that the inflammatory process that occurs in the airways in asthma is the key event in the modulation of BHR. Studies 15 Recently, it has been shown that inflammation also occurs in the airways of mildly asthmatic patients with normal pulmonary function but with BHR to histamine or methacholine. 16, 17 With respect to the ability to induce airway inflammation, the different stimuli can be divided into two groups. TM [2- agonists, anticholinergic drugs and xanthines have little, if any, anti-inflammatory activity, and that they have no significant long-term effects on airway reactivity. '4 On the other hand, drugs with an appreciable anti-inflammatory activity are already available (corticosteroids, sodium cromoglycate, nedocromil sodium) and other anti-inflammatory medications (cyclosporin, leukotriene antagonists, 5-1ipoxy-genase inhibitors, platelet activating factor receptor blockers) are being studied in the treatment of severe asthma. 25 In the following paragraphs, we will focus on the role of sodium cromoglycate and nedocromil sodium in inducing modifications of BHR and of the underlying inflammatory processes.
Sodium Cromoglycate
Since its discovery, sodium cromoglycate (SCG) was found to have minimal bronchodilatory effect in both animal and human models, while it showed significant activity in modulating inflammatory events involved in the pathogenesis of allergic diseases. In the past 30 years a large amount of research has been devoted to the study of the biological and clinical effects of SCG. Nevertheless, the basic mechanisms of action of this drug are not completely understood. 26 At present, there is a reasonable consensus on at least some aspects of the activity of SCG ( 34 and this is associated with an inhibitory effect on the allergen-induced hyper-responsiveness. 34, 5 Administration of SCG after the early response, but at least 60 min before the late response to allergen, caused a significant delay of LAR onset and a reduction in its duration. 6 Furthermore, the allergeninduced increase in methacholine responsiveness was also prevented. 6 Short-term studies which evaluated the protective effect of SCG against nonantigenic bronchial challenges showed variable results, depending on the bronchoprovocative agent utilized. Acute protection of SCG (40 mg, 10 min before challenge) to methacholine and histamine was observed by Woenne et al. 7 in 60% of a group of children with asthma. Mean change in BHR was +1.3 doubling doses (DD) and 0.8 DD when tested by methacholine and histamine, respectively. On the other hand, Cockcroft et al., 8 Griffin et al. 9 and Lemire et al. 4 failed to observe any significant protection of short-term SCG against BHR to histamine or methacholine.
SCG has a well-documented preventive effect against bronchoconstriction induced by exercise, 41, 42 cold air 4 and nonisotonic aerosol inhalation. 44 SCG is also more effective than atropine in preventing the asthmatic response to sulphur dioxide which is mediated by atropine-sensitive mechanisms, probably through irritant airway receptors. 45 Long-term studies substantially confirmed the protective effect of SCG against allergen inhalation challenge (2-4 weeks of administration) 4 and cold air (4 weeks). 9 In exercise-induced bronchoconstriction, the drug effectiveness was unaffected by its chronic use (1 year). 47 The results of chronic dosing of SCG upon histamine and methacholine challenge were conflicting when SCG was used for up to 8 weeks. Lack of activity was reported by some authors, 9,4s-5 while positive results--especially for 6 to 8 week studiesmwere observed by other investigators. 51,5" Conflicting results disappear when SCG is used chronically for more than 8 weeks. In such a case, a significant reduction of BHR, as measured by histamine or methacholine challenge, has been reported by most authors. 3, 47, 5 Nedocromil sodium Although nedocromil sodium (NS) differs structurally from SCG, they have many common mechanisms of action (Table 1) . NS reduces both early and late airway responses to allergen challenge by inhibiting mediator release from a variety of inflammatory cells. 54 It inhibits histamine secretion from both human BAL and dispersed lung mast cells, but its apparent activity varies markedly and inversely with the strength of the secretory stimulus. 55 NS also inhibits the release of PGD2 from human lung mast cells 5. and strongly decreases in vitro neutrophil and eosinophil mobilization caused by different chemotactic factors such as PAF and LTB4. 57 In an in vitro model of human bronchialtissue, NS inhibited the hyper-responsiveness induced by ionophore activated neutrophils presumably by modulating the release of prostaglandins and/or thromboxane from inflammatory cells. 58 NS also induces a significant inhibition of generation of cytotoxic mediators from both human monocytes and alveolar macrophages 59 and of the release of leukotrienes and 5-HETE from alveolar macrophages. In human neutrophils, a dose-dependent interference with Nformyl-methionyl-leucyl-phenylalanine (fMLP)-induced superoxide anion production and with fMLP binding was observed. 1, 6 Finally, the inhibition of bronchoconstriction induced by inhaled 
